DE-117 Drug Market

"DE-117 Market Size, Forecast, and Drug Insight – 2032” report provides comprehensive insights about DE-117 (Omidenepag isopropyl) for Glaucoma in the United States, and Japan. A detailed picture of the DE-117 (Omidenepag isopropyl)  for Glaucoma in the United states, and Japan for the study period 2019–2032 is provided in this report along with a detailed description of the DE-117 (Omidenepag isopropyl)  for Glaucoma. The report provides insight about mechanism of action, dosage and administration, as well as research and development activity including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the DE-117 (Omidenepag isopropyl) market forecast, analysis for Glaucoma in the United States and Japan, descriptive analysis such as SWOT, analyst views, comprehensive overview of market competitors, and brief about other emerging therapies in Glaucoma.

 

DE-117 Drug Summary

EYBELIS Ophthalmic Solution 0.002% (DE-117, Omidenepag Isopropyl) is an EP2 receptor agonist with a non-prostaglandin structure which is being developed by UBE Industries and Santen Pharmaceutical in Japan, Singapore, and the US for the treatment of glaucoma and ocular hypertension. Based on the Phase III trial results, Omidenepag isopropyl received approval in Japan in 2018 for glaucoma. 

Dosage

The recommended dose of omidenepag isopropyl ophthalmic solution (0.002%) is one drop in the eye, once daily. As per the Japanese label, careful administration is recommended in patients with ocular inflammatory diseases such as iritis, uveitis, and cystoid macular edema, as omidenepag isopropyl may worsen eye inflammation.

Mechanism of Action

Omidenepag isopropyl lowers the ophthalmic pressure via a dual mechanism of action, increasing both the trabecular outflow facility and the uveoscleral outflow as a result of EP2 receptor stimulation, thereby promoting aqueous outflow. It is an isopropyl ester derivative and undergoes hydrolysis to its active metabolite (omidenepag) during corneal penetration.

This summarizes the milestones in the development of omidenepag isopropyl ophthalmic solution (0.002%) leading to this first global approval for the treatment of glaucoma and ocular hypertension. It was being evaluated in the US for the same condition.

 

Scope of the DE-117 Drug Market Report

The report provides insights into:

• A comprehensive product overview including the DE-117 (Omidenepag isopropyl) description, mechanism of action, dosage and administration, research and development activities in Glaucoma.

• Elaborated details on DE-117 (Omidenepag isopropyl) regulatory milestones and other development activities have been provided in this report.

• The report also highlights the DE-117 (Omidenepag isopropyl) research and development activity in Glaucoma in detail across the United States, and Japan.

• The report also covers the patents information with expiry timeline around DE-117 (Omidenepag isopropyl).

• The report contains forecasted sales of DE-117 (Omidenepag isopropyl) for Glaucoma till 2032.

• Comprehensive coverage of the late-stage emerging therapies for Glaucoma.

• The report also features the SWOT analysis with analyst views for DE-117 (Omidenepag isopropyl) in Glaucoma.

 

DE-117 Methodology

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

DE-117 (Omidenepag isopropyl) Analytical Perspective by DelveInsight

• In-depth DE-117 (Omidenepag isopropyl)  Market Assessment

This report provides a detailed market assessment of DE-117 (Omidenepag isopropyl) in Glaucoma in the United States and Japan. This segment of the report provides forecasted sales data from 2022 to 2032.

• DE-117 (Omidenepag isopropyl)  Clinical Assessment

The report provides the clinical trials information of DE-117 (Omidenepag isopropyl) in Glaucoma covering trial interventions, trial conditions, trial status, start and completion dates.

 

DE-117 Drug Market Report Highlights  

• In the coming years, the market scenario for Glaucoma is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.   

• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence DE-117 (Omidenepag isopropyl) dominance.

• Other emerging products for Glaucoma are expected to give tough market competition to DE-117 (Omidenepag isopropyl) and launch of late-stage emerging therapies in the near future will significantly impact the market. 

• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of DE-117 (Omidenepag isopropyl) in Glaucoma.

• Our in-depth analysis of the forecasted sales data of DE-117 (Omidenepag isopropyl) from 2022 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the DE-117 (Omidenepag isopropyl) in Glaucoma. 

 

Key Questions

• What is the product type, route of administration and mechanism of action of DE-117 (Omidenepag isopropyl)?

• What is the clinical trial status of the study related to DE-117 (Omidenepag isopropyl) in Glaucoma and study completion date?

• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the DE-117 (Omidenepag isopropyl) development?

• What are the key designations that have been granted to DE-117 (Omidenepag isopropyl) for Glaucoma?

• What is the forecasted market scenario of DE-117 (Omidenepag isopropyl) for Glaucoma?

• What are the forecasted sales of DE-117 (Omidenepag isopropyl) in the United States and Japan?  

• What are the other emerging products available in Glaucoma and how are they giving competition to DE-117 (Omidenepag isopropyl) for Glaucoma?

• Which are the late-stage emerging therapies under development for the treatment of Glaucoma?